Lenacapavir: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Lenacapavir. Educational only — not medical advice.
Labeled uses
YEZTUGO is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating YEZTUGO [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ].
Source: FDA labeling via NIH DailyMed (set 1c241af1…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.